Table 2.
The effect of clinical characteristic variables on the tpCR.
| tpCR (n = 50) | p value | ||
|---|---|---|---|
| Yes (n = 24) | No (n = 26) | ||
| Age | 0.402 | ||
| ≤50 | 13 (54.2) | 11 (45.8) | |
| >50 | 11 (42.3) | 15 (57.7) | |
| Menopausal state | 0.982 | ||
| Postmenopausal | 11 (47.8) | 12 (52.2) | |
| Premenopausal | 13 (48.1) | 14 (51.9) | |
| Axillary lymph nodes involvement | 0.506 | ||
| Positive | 24 (50.0) | 24 (50.0) | |
| Negative | 0 (0.0) | 2 (100.0) | |
| Clinical stage | 0.571 | ||
| II | 11 (44.0) | 14 (56.0) | |
| III | 13 (52.0) | 12 (48.0) | |
| Ki-67 | 0.402 | ||
| ≤30% | 7 (41.2) | 10 (58.8) | |
| >30% | 17 (51.5) | 16 (48.5) | |
| Hormone receptor status | 0.271 | ||
| Positive | 12 (41.4) | 17 (58.6) | |
| Negative | 12 (57.1) | 9 (42.9) | |
| Tumor size stage | 0.459 | ||
| T1 | 2 (40.0) | 3 (60.0) | |
| T2 | 17 (50.0) | 17 (50.0) | |
| T3 | 1 (20.0) | 4 (80.0) | |
| T4 | 4 (66.7) | 2 (33.3) | |
tpCR, total pathological complete response.